Vitrafy Life Sciences Limited engages in the research, development, and commercialization of cryopreservation solutions in Australia. It offers cryopreservation medical devices, including freezers, thawers, and packaging solutions. The company also provides the LifeChain software platform, which controls, trace, tracks, and monitors quality of cryopreserved biomaterials, as well as the Guardion, non-medical hardware device. Its cryopreservation technology is used various applications, such as blood platelets, cell and gene therapies, and aquaculture and bovine breeding programs. Vitrafy Life Sciences Limited was incorporated in 2017 and is based in Melbourne, Australia.
Price analytics
Returns
1 day
-8.0%
1 week
4.7%
1 month
-9.4%
3 months
18.3%
6 months
96.7%
1 year
163.7%
3 years
—
Risk
Volatility (1y ann.)
75.6%
Beta vs ASX 200
0.35
Sharpe (1y)
1.59
VaR 95% (1-day)
-5.7%
Max drawdown (1y)
-28.9%
Off 1-year high
-23.1%
Technicals
RSI(14)
50
vs 50DMA
-5.0%
vs 200DMA
39.9%
Trend
Golden cross
Fundamental trends
Financial statements
Loading…
Scoring breakdown
(2 Oct 2026)
Value66.3
Trailing P/E
—
Forward P/E
100
PEG ratio
—
EV / EBITDA
100
Price / Book
20
Price / Sales
0
Growth100.0
Revenue growth (1y)
100
Revenue CAGR (3y)
100
EPS growth (1y)
—
EPS CAGR (3y)
—
Financial Health69.2
Net debt / EBITDA
—
Interest coverage (EBIT/interest)
0
Current ratio
100
Debt / Equity
100
Quality (Profitability & Cash Flow)24.2
Return on equity
0
Return on assets
0
Operating margin
100
Net margin
0
Cash conversion (OCF / net income)
—
Dividend / Income—
No meaningful dividend — pillar excluded from the overall score.
Momentum77.6
6-month return vs ASX 200
100
Price vs 200-day average
100
Price vs 50-day average
25
Position in 52-week range
68
Hover a row's info icon for the exact rule. Bounds and weights are configurable in
the Django admin (Scoring configuration).